December 8, 2021
Janssen Pharmaceutical K.K. said on December 7 that it has made a Japan submission for its investigational CAR-T cell treatment ciltacabtagene autoleucel (cilta-cel) for the indication of relapsed or refractory multiple myeloma (MM). The treatment is intended for MM patients...read more